|Mr. Thomas K. Equels Esq., J.D., M.S.||Exec. Vice Chairman, CEO & Pres||1.52M||N/A||1953|
|Ms. Ellen M. Lintal||CFO & Chief Accounting Officer||441.99k||N/A||1959|
|Mr. Peter W. Rodino III, Esq., J.D.||COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.||681.86k||N/A||1951|
|Dr. David R. Strayer||Chief Scientific Officer & Medical Director||N/A||N/A||1946|
|Ann Marie E. Coverly||Director of Admin. & HR and Deputy Investor Relations Coordinator||N/A||N/A||N/A|
|Dr. Carol A. Smith||Chief Manufacturing Officer & Deputy Chief Scientific Officer||N/A||N/A||1951|
|Dr. Ralph Christopher Cavalli||VP of QC & Manufacturing||N/A||N/A||1958|
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
AIM ImmunoTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.